Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 17
Submit an article Journal homepage
476
Views
27
CrossRef citations to date
0
Altmetric
Review

Polycystic ovary syndrome: treatment strategies and management

Héctor F Escobar Morreale Hospital Universitario Ramón y Cajal, Centro de Investigación Biomédica en Red de Diabetes y, Enfermedades Metabólicas Asociadas (CIBERDEM), Department of Endocrinology, Carretera de Colmenar Km 9'1, E-28034, Madrid, Spain +34 91 336 9029; +34 91 336 9029; [email protected]
, MD PhD
Pages 2995-3008 | Published online: 12 Nov 2008

Bibliography

  • Diamanti-Kandarakis E, Christakou C. Prevalence, definition and clinical anifestations of polycystic ovary syndrome. Endocrinol Nutr 2006;53(Suppl 1):25-33
  • Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-8
  • Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-11
  • Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9
  • Kumarapeli V, Seneviratne RDA, Wijeyaratne CN, et al. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semiurban population in Sri Lanka. Am J Epidemiol 2008;10.1093/aje/kwn137
  • Azziz R, Carmina E, Dewailly D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-45
  • Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26:251-82
  • Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Human ovarian theca cells in culture. Trends Endocrinol Metab 2006;17:65-71
  • Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266-72
  • Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13:251-7
  • Gambineri A, Pelusi C, Vicennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-96
  • Jakubowicz DJ, Nestler JE. 17 α-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997;82:556-60
  • Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36
  • Jakubowicz D, Maman D, Essah P. Effect of diet with high carbohydrate and protein breakfast on weight loss and appetite in obese women with metabolic syndrome. The Endocrine Society's 90th Annual Meeting; 2008 June 15-18, 2008; San Francisco; 2008
  • Sabuncu T, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril 2003;80:1199-204
  • Jayagopal V, Kilpatrick ES, Holding S, et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 2005;90:729-33
  • Cho L, Kilpatrick E, Keevil B, et al. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008 Jun 10. [Epub ahead of print]
  • Florakis D, Diamanti-Kandarakis E, Katsikis I, et al. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obes (Lond) 2008;32:692-9
  • Lindholm A, Bixo M, Bjorn I, et al. Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2008;89:1221-8
  • Aronne LJ, Isoldi KK. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. Am J Cardiol 2007;100:P18-26
  • Sathyapalan T, Cho L, Kilpatrick ES, et al. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome: a randomised open-labelled parallel study. Clin Endocrinol (Oxf) 2008 [Epub ahead of print]
  • Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142:547-59
  • Solomon CG, Dluhy RG. Bariatric surgery – quick fix or long-term solution? N Engl J Med 2004;351:2751-3
  • Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37
  • Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93
  • Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005;90:6364-9
  • Gambineri A, Pasquali R. Insulin resistance, obesity and metabolic syndrome in polycystic ovary syndrome. Endocrinol Nutr 2006;53(Suppl 1):49-55
  • Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54
  • De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633-67
  • Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-23
  • Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46
  • Harborne L, Fleming R, Lyall H, et al. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4116-23
  • Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;CD003053
  • Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524-9
  • Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004;10:323-34
  • Khattab S, Mohsen IA, Foutouh IA, et al. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006;22:680-4
  • Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-66
  • Diamanti-Kandarakis E, Baillargeon J-P, Iuorno MJ, et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927-32
  • Pasquali R, Gambineri A. Insulin-sensitizing agents in women with polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S28-9
  • Iuorno MJ, Nestler JE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:153-64
  • Larner J, Allan G, Kessler C, et al. Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. J Basic Clin Physiol Pharmacol 1998;9:127-37
  • Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314-20
  • Odlind V, Weiner E, Victor A, Johansson ED. Effects on sex hormone binding globulin of different oral contraceptives containing norethisterone and lynestrenol. Br J Obstet Gynaecol 1980;87:416-21
  • Darney PD. The androgenicity of progestins. Am J Med 1995;98:S104-10
  • Costello M, Shrestha B, Eden J, et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev 2007:CD005552
  • Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005;152:269-75
  • Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2453-61
  • Vexiau P, Fiet J, Conard J, et al. 17 beta-Estradiol: oral or parenteral administration in hyperandrogenic women? Metabolic tolerance in association with cyproterone acetate. Fertil Steril 1995;63:508-15
  • Moghetti P. Treatment of polycystic ovary syndrome with insulin sensitizers and antiandrogens. Endocrinol Nutr 2006;53(Suppl 1):63-8
  • De Leo V, Lanzetta D, D'Antona D, et al. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99-102
  • Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo- controlled trial. J Clin Endocrinol Metab 2000;85:89-94
  • Wallace C, Lalor EA, Chik CL. Hepatotoxicity complicating flutamide treatment of hirsutism. Ann Intern Med 1993;119:1977
  • Garcia Cortes M, Andrade RJ, Lucena MI, et al. Flutamide-induced hepatotoxicity: report of a case series. Rev Esp Enferm Dig 2001;93:423-32
  • Dikensoy E, Balat O, Pence S, et al. The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Arch Gynecol Obstet 2008 [Epub ahead of print]
  • Falsetti L, Pasinetti E. Treatment of moderate and severe hirsutism by gonadotropin-releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil Steril 1994;61:817-22
  • Pazos F, Escobar-Morreale HF, Balsa J, et al. Prospective randomized study comparing the long-acting gonadotropin- releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil Steril 1999;71:122-8
  • Azziz R. Use of combination oral contraceptives in the treatment of hyperandrogenism and hirsutism. In: Rose BD, editor. UpToDate. Waltham, MA: UpToDate, Inc., 2007
  • Luque-Ramirez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Hum Reprod 2008;23:1594-601
  • Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril 2008 [Epub ahead of print]
  • Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero JI, et al. The increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism, and do not result from reduced menstrual losses. Diabetes Care 2007;30:2309-13
  • Escobar-Morreale HF, Luque-Ramirez M, Alvarez-Blasco F, et al. Body iron stores are increased in overweight and obese women with polycystic ovary syndrome. Diabetes Care 2005;28:2042-4
  • Abodeely A, Roye GD, Harrington DT, Cioffi WG. Pregnancy outcomes after bariatric surgery: maternal, fetal, and infant implications. Surg Obes Relat Dis 2008;4:464-71

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.